Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025020 | 0.90 | TSHR (0.49) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4714622 | 0.88 | TSHR (0.56) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4711870 | 0.86 | HTT (0.52) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL1853562 | 0.84 | KMT2A (0.50) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4019040 | 0.84 | HTT (0.52) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL1853649 | 0.78 | ALDH1A1 (0.46) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4714646 | 0.78 | TSHR (0.47) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4717987 | 0.78 | TSHR (0.47) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4715407 | 0.76 | SMN1; SMN2 (0.69) | HTTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4025022 | 0.75 | TSHR (0.49) | HTTMEN1KMT2ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | HTT 4318/4885MEN1 2947/4885KMT2A 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.